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Objectives: Pharmacogenetic (PG) algorithms of warfarin dosing have been proposed 
as potential improvement of anticoagulation control. Despite several randomized clin-
ical trials, the clinical benefit was not consistently proven. The objective of this study 
was to estimate the opportunity cost of introduction of warfarin PG testing into health 
system using an expected value of perfect information (EVPI) approach. MethOds: 
Previously developed cost-effectiveness model was employed to evaluate the PG 
algorithm-based warfarin dosing versus standard treatment. Differences in antico-
agulation control, in terms of percentage of time in therapeutic range (TTR), were used 
to simulate thromboembolic and haemorrhagic events. The outcomes were valued 
in quality-adjusted life-years (QALY) and 2014 cost. Uncertainty in the model param-
eters was assessed using probabilistic sensitivity analysis and EVPI was estimated 
at a threshold of 25,000 EUR/QALY gained. Results: In the base case, where price 
of PG test was 40 EUR, the ICER of genotype-guided treatment was 8.146 EUR/QALYg 
compared to the standard treatment. When uncertainty about clinical efficacy was 
examined, ICER ranged from approximately 1.000 EUR/QALYg to dominated strategy. 
Another important factor was the price of PG test. In the base case, the treatment 
using PG algorithm had highest expected net-benefit with opportunity loss surround-
ing uncertainty about clinical efficacy of 2.9 EUR per treated patient. Conversely, 
increasing the cost of PG test by 3 times, to 120 EUR, resulted in the highest total 
expected net-benefit for standard treatment. Selecting the genotype-guided treat-
ment instead of standard therapy would result in opportunity loss of 47.2 EUR, while 
EVPPI for standard treatment was 0.82 EUR. cOnclusiOns: The price of PG test is 
an important factor about decision of warfarin PG introduction into health system 
or investment into additional clinical trials. The smaller cost of PG test means lower 
opportunity cost, consequentially future research should not have important impact 
on economic aspect of decision.
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Objectives: In the prescription of pharmaceutical therapies for the chronic dis-
eases there is the responsibility both the hospital specialist doctor and the one 
territorial. A responsibility that can not be distinguished by the enterprise informa-
tion systems. Purpose of the study is the development of an informatic framework 
to implement specific training plans on the hospital’s doctors in order to reduce 
the prescription of the ACE-inhibitors compared to the ARBs. MethOds: It has 
been used 2014 data of pharmaceutical prescriptions of ACE-inhibitors and ARBs, 
outpatient specialistic for cardiology visits, of hospital admissions by the Polyclinic 
of Modena, in an observational cohort study of record linkage, identifying for each 
outpatient service and of hospitalization the pharmaceutical prescription 30 days 
later 60 days prior the hospital activity. Results: It has been analysed 3,5 Billion 
outpatient prescriptions and 27.529 hospitalizations, noting that naive patients 
have received 51% of ACE-inhibitors, 64% of patients has changed his own ther-
apy from ARBs to ACE-inhibitors, while 28% has a stable therapy after cardiology 
visits. cOnclusiOns: The model has allowed to distinguish the pharmaceutical 
therapy accomplished by the hospital’s doctors compared to the one of the doc-
tors of general medicine, highlighting also the therapies changed by the doctors of 
general medicine, in the absence of a focused informative system. The new data 
framework will support a face to face training.
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Objectives: To investigate whether usage patterns differ for different indications 
of angiotensin converting enzyme inhibitors (ACE-inhibitors). MethOds: Patients 
older than 45 years who started ACE-inhibitor treatment between January 2007 
and January 2014 were selected in the Clinical Practice Research Datalink (CPRD). 
Indications for ACE-inhibitor treatment were retrieved from the medical records. 
Stratified by indication we distinguished between continuous use, discontinued 
use, switch to an alternative drug, and restart, considering a 6 months’ time interval 
between two prescription periods. Five-years persistence rates among the differ-
ent indications were calculated using the Kaplan-Meier method and compared by 
the log-rank test. Results: In total 276,977 patients initiating ACE-inhibitors were 
identified with the following indications: hypertension (56.9 %), myocardial infarc-
tion (4.3%), renal failure (3.7%), heart failure (1.6%), combinations of them (17%) and 
none of the above (16.5%). Five-year persistence rates ranged from 44.1% for renal 
failure to 68.9% for myocardial infarction (p< 0.0001). Heart failure and renal failure 
patients used ACE-inhibitors for the shortest period of time (average 21.8 and 21.9 
months, respectively). Within the discontinuation group the percentages of switch-
ers ranged from 35.9% for renal failure to 53.9% for hypertension (61.0% switched to 
an angiotensin II-receptor blocker) and for the restarter group ranged from 15.0% for 
heart failure to 18.1% for the group without indication retrieved. cOnclusiOns: 
Dependent on the indication the rates of ACE-inhibitor discontinuation differ. 
Patients with renal failure are most likely to discontinue treatment.
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Objectives: Japan has universal health coverage, and, regulations concerning med-
ical reimbursements are loose in the prescription, with physicians having a high 
degree of discretion in prescriptions. There is no upper limit or reference pricing, and 
as both physicians and patients prefer brand drugs, there has been a lack of progress 
a patient with stroke lives and which factors most influence survival in stroke 
in Turkey. MethOds: Based on Elixhauser Comorbidity Index, data for patients 
diagnosed at least with stroke or 17 chronic diseases such as hypertension, diabe-
tes, heart diseases were collected from Turkish SocSecurity Institution database 
between 2008 and 2013. Then with simple random sampling method, a sample of 
2,113 ischemic stroke and 155 hemorrhagic stroke patients were selected. Two Cox 
regression models were run to identify which factors impact the survival years and 
how much they reduce survival for each stroke type. Finally survival months were 
calculated. Results: Among dead patients, a patient with stroke lived less than a 
year on average. 14%, 11%, 11% and 14% percent of stroke patients died 1-2 years, 2-3 
years, 3-4 years and more than 4 years respectively. In the first model the average 
survival month for an ischemic stroke patient was 35. Age and gender didn’t change 
survival months statistically. Hypertension, diabetes, heart disease and nervous 
system diseases reduced survival months by 4, 12, 7 and 9 months respectively with 
95% confidence level. In the second model a hemorrhagic patient lived 39 months 
on average. A patient younger than 55 experienced 10 months longer lives than a 
patient over 55. Gender again didn’t incorporate any chance to survival. In addi-
tion, a patient with no hypertension and heart disease enjoyed 24 and 19 months 
longer lives respectively. cOnclusiOns: In Turkey, the chance of living longer for 
ischemic stroke patients drops if the patients were diagnosed with hypertension, 
diabetes, heart disease or nervous system disease. Older patients with hemorrhagic 
stroke lived less, hypertension and heart disease adversely affected survival months.
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Objectives: Stroke is a severe disease that leads one of the main causes of death and 
disability affecting approximately 15 million people worldwide. This study aims at 
analyzing summary statistics of stroke in Turkey. MethOds: Data was collected for 
the patients diagnosed with stroke from Turkish Social Security Institution database 
between 2008 and 2013. Prevalence, gender and age distribution of the disease were 
computed. Then basic statistics of each type of the disease were analyzed. Results: 
Between 2008 and 2013 1.9 million people were diagnosed with stroke. Among those 
patients, 44% and 56% were males and females respectively. Over 6 years roughly 400 
thousand diagnosed patients died and as of December 31, 2013 nearly 1.5 million peo-
ple had stroke with a prevalence of 2%. The prevalence for females (2.2%) was higher 
than that of males (1.7%), higher for 0-74 age group but lower for 75+. The prevalence 
rises as age increases, 75+ population had 62, 12, 2 times higher risk of having stroke 
compared to 0-25, 35-44 and 55-64 age groups. In our study, stroke is divided into four 
subgroups: ischemic stroke, sequels, hemorrhagic stroke and unknown stroke. 84% 
of all cases was recorded as ischemic stroke (getting the largest share parallel to the 
literature), 9% as sequels, 5% hemorrhagic stroke and only 2% is unknown stroke. 
While 0-44 age group aggregated 13.2% of all ischemic stroke patients, the figure hiked 
28.1% for hemorrhagic stroke patients. cOnclusiOns: Stroke is one of the leading 
causes of death in Turkey and the prevalence in 2013 totaled 2% of Turkish population. 
Considering that Turkey is aging rapidly in spite of having a young population, the 
number of cases with stroke will grow in near future, signaling higher stroke related 
death figures if no action is taken.
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Objectives: Coronary heart disease (CHD) treatment has seen significant improve-
ments due to new health technologies (HT) in interventional cardiology. Health sys-
tems (HS) adopt new HT at different speed and use rates, which may become more 
apparent when contrasting between HS with distinct features. We characterized and 
compared the ability of the HS of United States (US) and Portugal (PT) to access and 
use new HT to treat CHD. MethOds: A total of 30 HT between January 1980 and 
February 2015, including medical devices and active substances, were identified by 
experts and reviewed. Approval/commercialization dates of the first medical devices 
models and active substances brands were abstracted using databases at the local 
regulatory agencies and complemented with other sources of information when nec-
essary. Differences between dates were used for comparison between countries. We 
additionally performed an extensive literature review and retrieved information on 
use trends of these HT in PT versus US. Results: Most medical devices reviewed were 
approved earlier in PT than in US (median time difference: 27 months), whereas drugs 
were more readily available in US (median time difference: 61 months). Furthermore, 
while all HT are currently approved in PT, the drug-eluting balloon, Nicorandil and 
Ivabradine lack approval in US. Utilization patterns vary across devices but evidence 
suggests that adoption in PT is sometimes deferred from approval and that the US 
generally reaches similar or higher utilization rates than PT. Commercialization of 
drugs in PT was delayed by a median of 65 months from approval. cOnclusiOns: 
Regulatory mechanisms of approval and price controls are determinant in the type of 
HT available. However, other factors appear to play an important role in the diffusion 
of new HT. Differences in use could be explored for mutual benefit for assessing and 
monitoring safety and cost-effectiveness of HT between the two HS.
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embolism (PE) in 2007-2011 were identified for whom out-patient pharmacy dis-
pensing data was available. Cancer, other risk factors and type and duration of 
anticoagulant treatment (LMWH and/or VKA) within 90 days of diagnosis and recur-
rence of VTE were assessed. Results: The study cohort included 1,581 VTE patients: 
1,053 with DVT and 528 with PE. For 70-86% of the VTE patients, dispensings of 
anticoagulant treatment were observed within 90 days. The median duration of anti-
coagulant dispensings among patients for whom both LMWH and VKA dispensings 
were observed was 3.5 months with provoked VTE and 3.7 months with unprovoked 
VTE. In these cohorts the observed median dispensing duration of (initial) LMWH 
treatment was 12 days. Recurrent VTE occurred mostly after discontinuation of anti-
coagulant treatment. Longer dispensing durations were observed among patients 
without recurrence. cOnclusiOns: Treatment after VTE as captured in obser-
vational healthcare data generally follows the Dutch guidelines. However, many 
patients received LMWH dispensing covering periods longer than the recommended 
5-10 days. Furthermore, among patients with a VTE recurrence shorter duration of 
anticoagulant treatment was observed compared to patients without a recurrence.
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Objectives: Oral anticoagulation (OAC) is the mainstay of stroke prevention in 
NVAF. With the arrival of NOACs as an alternative to VKA, there is interest in the 
utilization of these classes. This study aimed to describe treatment patterns and 
estimate persistence to VKA and NOACs in NVAF patients. MethOds: Retrospective 
cohort study (Jan 2003-Dec 2013) of patients newly diagnosed with NVAF from the 
Badalona Serveis Assistencials database. Change in treatment line was defined 
as discontinuation (absence of prescription for ≥ 90 days) or switch. We calculated 
the cumulative incidence (95% CIs) of persistence after treatment initiation by 
treatment line, accounting for death as a competing risk. Results: Overall, 2,137 
patients initiated an OAC (VKA/NOAC) during the study period, with VKA most fre-
quently prescribed [2,127 patients (99.5%) vs. 300 patients (14.0%) initiating NOAC]. 
VKA was the predominant 1st line OAC following NVAF diagnosis (2,127; 99.5%). 
For patients initiating 2nd line treatments (589), half (298; 50.6%) restarted VKA 
after previous VKA treatment and cessation; and half (290; 49.2%) switched from 
VKA to a NOAC. Almost all NOAC initiations were patients previously treated with 
VKA (291/300 patients; 97%). Persistence to VKA was lower in 1st line than 2nd line 
patients (median time to discontinuation/switch: 156 vs. 181 days). Persistence to 
NOACs was not calculated for 1st line patients due to low numbers; but for patients 
initiating NOAC as 2ndline, the median time to NOAC discontinuation/switch was 
241 days. cOnclusiOns: In this study, almost all patients initiating a 1st line OAC, 
initiated VKA, with essentially no first-line NOAC prescription. Unadjusted persis-
tence was best for patients initiating a NOAC as a 2nd line, and the shortest among 
patients initiating VKA as 1st line. As more patients are treated with NOACs in 
Spain, future research on treatment patterns should allow adjustment of persis-
tence comparisons between OACs.
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Objectives: Poor adherence to cardiovascular therapy is increasingly demonstrated 
to contribute to poor health outcomes, leading to increased hospitalization rates. 
This study aims to quantify the potential economic implications of non-adherence 
to statins in Belgium, from the payer perspective. MethOds: Adherence levels were 
estimated based on IMS Health Lifelink Treatment Dynamics database (IMS Health 
LTD). The number of prescription re-fills and total days covered by prescriptions 
were counted. Patients were assumed to take one pill per day. Dividing the total 
number of pills by the days of follow-up per patient resulted in the %-adherence 
level. The number of avoidable hospitalizations corresponding to each adherence 
level was determined by: the hospitalization risk difference between patients at 
80-100% adherence and less than 80% adherence (grouped per 20%, Sokol et al 
2005), and multiplying the number of patients in each of the five adherence lev-
els in Belgium (extrapolated from IMS Health LTD according to Pharmanet 2013 
report). The total avoidable cost attributable to non-adherence was estimated, by 
multiplying the number of avoided hospitalizations due to non-adherence with the 
average cost of a cardiovascular hospitalization in Belgium in 2014 (€ 5,865), adding 
the extra drug cost needed to obtain a 80-100% adherence. Results: Sixty-five 
percent of anonymized patients in the IMS Health LTD were below the acceptable 
80% adherence level. A total of 25,716 cardiovascular hospitalizations in Belgium 
were possibly attributable to lack of adherence to statins therapy. The estimated 
total avoidable costs related to hospitalization would be € 150.8Mn. If all patients 
raised their levels of adherence to 80-100%, treatment costs with statins would 
increase with € 68.5Mn. Thus, the estimated total amount of savings would be around 
€ 82.4Mn. cOnclusiOns: Correcting poor adherence, not only in the cardiovascular 
area, can lead to important savings and give air to the healthcare payer to invest 
in innovative drugs.
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in the use of generic drugs.It is possible that even patients who have continually 
been prescribed generic drugs may switch to Protected Brand Drugs when they 
reimburse. The purpose of this study was to clarify this switch of patients to whom 
generic drugs had been prescribed to Brand Drugs using nationwide administrative 
data. MethOds: Using dispensation data of pharmacies on an annual basis from 
April 2011 to December 2014, we identified all prescriptions for DM, Hypertension 
and Hyperlipidemia.1) We targeted patients prescribed only generic drugs between 
April and September each year, and who have dispensation records for three months 
or longer. 2) Where there was a change to the brand drug from a patient from Oct 
to March each year, this was defined as a drug switch. In terms of data analysis, we 
used SQL Server 2008 R2 for data handling and R for data analysis. Results: From 
among the patients with diabetes (N= 181,378), hypertension (343,188) and hyper-
lipidemia (343,188), those matching condition 1) in 2012 were patients with diabetes 
(n= 44,533), hypertension (132,165) and hyperlipidemia (81,455). 31% of all patients 
were continually prescribed only generic. The switch from generic to Protected 
Brand Drugs was higher in the younger 40-50 age group (p= 0.05) than in the elderly 
generation, and there was a higher rate of males (p= 0.05). cOnclusiOns: The 
results of this study showed that when promoting drug substitution to generic drugs 
as a policy for reducing medical costs, it is also necessary to consider measures to 
counteract the shift to brand drugs.
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Objectives: To study the pattern of prescription of antihypertensive agents among 
the patients visiting Cardiology department MethOds: This is a cross sectional 
study conducted in collaboration with Department of Cardiology, College of Medical 
Sciences and Teaching Hospital, Bharatpur, Chitwan during the period of three 
months (1st January to 31st March 2015). All the patients attending the outpatient 
department of Cardiology and prescribed antihypertensive drugs were taken as 
sample. Results: Among the total 382 patients studied, the mean age was 58.53 ± 
12.295 years. Males contributed to 219 (57.32%) and females 163 (42.67%) cases. Mean 
body mass index was 23.64 ± 5.29 Kg/m2. Two hundred forty (63.35%) patients were 
given combination therapy and 140 (36.64%) were treated with a single drug. Two 
drug combination was given in 147 (38.48%) cases, three drugs in 63 (16.49%), four 
in 20(5.23) and five drugs in 12 (3.14%) cases. Angiotensin receptor antagonists (42 
or 30%), followed by calcium channel blockers (39 or 27.85%) were the most com-
monly prescribed drugs in 140 monotherapy cases. Combination of furosemide and 
spironolactone (101) was the most common single drug delivery system prescribed 
which was followed by metoprolol (88). cOnclusiOns: The above findings would be 
useful for physicians and clinical pharmacologists in evaluating rational prescrib-
ing of the antihypertensive medicines. The inadequacy of control of blood pressure 
by monotherapy has increased the trend for combination therapy. The common 
antihypertensive used were angiotensin receptor antagonists.
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Objectives: To assess adherence with therapeutic guidelines in the treatment of 
venous thromboembolism and pulmonary embolism in clinical practice. MethOds: 
An observational retrospective analysis on six Local Health Units’ administrative 
and laboratory test databases was conducted, with around 2.7 Million beneficiar-
ies involved. Patients discharged alive from a hospitalization with a diagnosis of 
venous thromboembolism and pulmonary embolism between January 1st, 2010 and 
December 31st, 2012 were included. Since the index date (date of discharge), patients 
were characterised and followed-up basing on previous and following 12 months, 
respectively. Results: A total of 4,499 patients were included in the analysis. More 
prevalent therapeutic patterns and sequences occurred as follows. Among included 
patients, considering all the follow-up period, 33% had heparin only (average dura-
tion of heparin treatment equal to 143 days), 26% had vitamin K antagonist (VKA) 
only, 4% had fondaparinux only, and 12% had none of the previous treatments. 
Eight percent of included patients were initially prescribed for VKA and combined 
heparin during the follow-up period (average duration of heparin treatment equal 
to 76 days), 4% were initially prescribed for heparin (average duration of hepa-
rin treatment equal to 150 days) and combined VKA during the follow-up period. 
Four percent of included patients were initially prescribed for VKA and switched 
to heparin during the follow-up period (average duration of heparin treatment 
equal to 99 days) while 3% were initially prescribed for heparin (average duration 
of heparin treatment equal to 75 days) and switched to VKA during the follow-up 
period. cOnclusiOns: Adherence with therapeutic guidelines in the treatment of 
venous thromboembolism and pulmonary embolism in clinical practice appeared 
unsatisfactory since a high percentage of patients are treated with heparins for time 
period longer than recommended instead of switching to VKAs.
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Objectives: To describe initial anticoagulant treatment after venous thrombo-
embolism (VTE) as recorded in electronic healthcare records and relate this to 
the underlying risk factors, guidelines and recurrence rates. MethOds: From the 
PHARMO GP Database, patients with deep venous thrombosis (DVT) or pulmonary 
